- Home
- CABA vs CTW Comparison
CABA vs CTW Comparison
Compare CABA & CTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- CTW
- Stock Information
- Founded
- CABA 2017
- CTW 2013
- Country
- CABA United States
- CTW Japan
- Employees
- CABA 167
- CTW N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- CTW EDP Services
- Sector
- CABA Health Care
- CTW Technology
- Exchange
- CABA Nasdaq
- CTW Nasdaq
- Market Cap
- CABA 174.7M
- CTW 171.4M
- IPO Year
- CABA 2019
- CTW 2025
- Fundamental
- Price
- CABA $2.04
- CTW $1.91
- Analyst Decision
- CABA Strong Buy
- CTW
- Analyst Count
- CABA 8
- CTW 0
- Target Price
- CABA $12.75
- CTW N/A
- AVG Volume (30 Days)
- CABA 1.3M
- CTW 57.6K
- Earning Date
- CABA 11-13-2025
- CTW 01-01-0001
- Dividend Yield
- CABA N/A
- CTW N/A
- EPS Growth
- CABA N/A
- CTW N/A
- EPS
- CABA N/A
- CTW N/A
- Revenue
- CABA N/A
- CTW $76,194,020.00
- Revenue This Year
- CABA N/A
- CTW N/A
- Revenue Next Year
- CABA N/A
- CTW N/A
- P/E Ratio
- CABA N/A
- CTW $44.58
- Revenue Growth
- CABA N/A
- CTW 8.71
- 52 Week Low
- CABA $0.99
- CTW $1.71
- 52 Week High
- CABA $5.46
- CTW $4.88
- Technical
- Relative Strength Index (RSI)
- CABA 71.47
- CTW N/A
- Support Level
- CABA $1.63
- CTW N/A
- Resistance Level
- CABA $1.74
- CTW N/A
- Average True Range (ATR)
- CABA 0.12
- CTW 0.00
- MACD
- CABA 0.05
- CTW 0.00
- Stochastic Oscillator
- CABA 89.44
- CTW 0.00
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.